REDEFINE 3

Clinical Study: Cardiovascular Disease

Aspirus Research Institute is seeking participants for a clinical study that has the potential to improve future treatment options for people living with cardiovascular disease.

The REDEFINE 3 Study will look at the safety and potential benefits of cagrilintide and semaglutide (CagriSema) on cardiovascular events, like heart attack and stroke, in people living with cardiovascular disease. During the study, researchers will track cardiovascular events (heart attack, stroke, or heart-related deaths) as well as changes in body weight and A1C.

Learn More About Clinical Trials

Participants may qualify if they:

• Had a stroke, heart attack, or have poor circulation (peripheral artery disease)
• Are 55 years of age or older
• Are considered overweight or living with obesity (BMI>25)
• Have type 2 diabetes
• Can have chronic kidney disease
• Can attend regular clinic visits and receive phone calls over 4 - 4.5 years, depending on study start date

To find out more:
Aspirus Research Institute
715-847-2273
research@aspirus.org